Clinical trials: Dialysis
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.
- Trial name
- Dolomites (NCT02021318)
- Testing
- Roxadustat, Darbepoetin alfa
- Where
- 125 sites in Austria, Belarus and 24 more
- Volunteers
- 616 people
- Sponsor
- Astellas Pharma Europe B.V.
Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991
Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after oral administration to patients with chronic kidney disease undergoing hemodialysis.
- Conditions
- Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy, Pharmacodynamics of ASP7991, Pharmacokinetics of ASP7991
- Trial name
- NCT01872026
- Testing
- ASP7991
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Anemia in Chronic Kidney Disease Patients Not on Dialysis
ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-
This study is to evaluate the safety and the dose-response of ASP1517 in the treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied intermittently.
- Trial name
- NCT01964196
- Testing
- ASP1517
- Where
- 7 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Astellas Pharma Inc
Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
The objective of this study is to evaluate the safety and efficacy of ASP1517 in peritoneal dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT02780726
- Testing
- roxadustat
- Where
- 15 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Astellas Pharma Inc
Dialysis, Healthy Subjects
An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
The purpose of the study is to determine whether ASP0113 (a CMV deoxyribonucleic acid [DNA] vaccine) can be detected in plasma after intramuscular (IM) injections, and to determine whether CMV-seropositive healthy volunteers…
- Conditions
- Dialysis, Healthy Subjects, Cytomegalovirus Infection
- Trial name
- NCT02103426
- Testing
- ASP0113
- Where
- 4 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Renal Anemia in Non-dialysis Chronic Kidney Disease
SAL-0951 Tablets in the Treatment of Renal Anemia in Non-dialysis Chronic Kidney Disease
This study is a phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of SAL-0951 in CKD-anemia patients in Non-dialysis, comprising 8 weeks of double-blind treatment period…
- Trial name
- NCT06016036
- Testing
- SAL-0951
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Chronic Kidney Disease Requiring Chronic Dialysis
A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood).
- Trial name
- NCT06218290
- Testing
- Oxylanthanum Carbonate
- Where
- 7 sites in United States
- Volunteers
- 106 people
- Sponsor
- Unicycive Therapeutics, Inc
Renal Dialysis, Kidney Failure, Chronic
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with…
- Trial name
- NCT03873038
- Testing
- MK-2060
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Fluid Loss, Dialysis
Clinical Evaluation of the CM-1500 During Hemodialysis
The study is a prospective, single-arm, non-randomized, non-blinded, non-controlled, non-significant risk, single center study enrolling up to 20 subjects consented to undergo a hemodialysis session as a part of their standard…
- Trial name
- NCT05125848
- Testing
- CM-1500
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Zynex Monitoring Solutions
Dialysis; Complications, Central Vein Obstruction
APERTO CVS PMCF Study
Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients
- Conditions
- Dialysis; Complications, Central Vein Obstruction, Stenosis, Restenosis
- Trial name
- APERTO CVS (NCT04514406)
- Testing
- APERTO OTW DCB
- Where
- 2 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Cardionovum GmbH
COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure)
A Pilot Observation and Feasibility Study of Prevora, Integrated Into Homecare Visits of High-risk Adults
Prevora is an antiseptic medication and dental treatment approved by Health Canada for reducing root decay (cavities) in adults at high risk of dental decay. An antiseptic kills germs and harmful bacteria.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), CHF (Congestive Heart Failure), Dialysis, Chronic Metabolic Disorder
- Trial name
- NCT06158633
- Testing
- Prevora
- Volunteers
- 30 people
- Sponsor
- CHX Technologies Inc.
Dialysis Access Malfunction
The ReModel IHC Study for ESRD Patients
There will be two phases of this study. The phases of this study may occur simultaneously. In Phase I, eligible subjects will be asked to acutely wear the Alio Medical RMS SmartPatch during regularly scheduled dialysis sessions.
- Trial name
- NCT05039541
- Testing
- Alio Device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alio, Inc.
End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis
A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis
This study aims to determine if the CloudCath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.
- Conditions
- End Stage Renal Disease, Peritoneal Dialysis-associated Peritonitis, Peritonitis
- Trial name
- ACT (NCT05285436)
- Testing
- CloudCath System
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- CloudCath
Peritoneal Dialysis-associated Peritonitis, End Stage Renal Disease
In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device
A proof-of-concept study of a prototype CloudCath device designed to detect peritonitis using the effluent dialysate from patients undergoing peritoneal dialysis.
- Trial name
- NCT05300191
- Testing
- Effluent dialysate
- Where
- Mexico
- Volunteers
- 500 people
- Sponsor
- CloudCath
End Stage Renal Disease on Dialysis
The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300
Study Goal is to determine the impact of dialysate flow rate (Qd) on Subject reported dialysis related symptoms and on time to recovery post dialysis.
- Trial name
- NCT05947708
- Testing
- Dialysate Flow Rate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Outset Medical
Peritoneal Dialysis-associated Peritonitis
A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis
This study aims to determine if the CloudCath device can detect infections related to peritoneal dialysis (peritonitis) as fast or faster than the current standard methods used by patients and doctors to detect such infections.
- Trial name
- CATCH (NCT04515498)
- Testing
- CloudCath Monitoring System
- Where
- United States
- Volunteers
- 243 people
- Sponsor
- CloudCath
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy.
- Trial name
- OPTIMIZE (NCT04549597)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- Ardelyx
Peritoneal Dialysis-associated Peritonitis
Neutrophil Gelatinase-Associated Lipocalin (NGAL) Rapid Test (Colloidal Gold) Clinical Trial Protocol
According to the requirements of the "Technical Guidelines for Clinical Trials of In Vitro Diagnostic Reagents", the first registered product (hereinafter referred to as the assessment reagent) - Neutrophil Gelatinase-Associated…
- Trial name
- NCT05450523
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Qingdao HIGHTOP Biotech Co., Ltd.
Anemia, Dialysis-dependent Chronic Kidney Disease
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.
- Trial name
- FO2RWARD-2 (NCT03799627)
- Testing
- Vadadustat, Epoetin Alfa, Vadadustat TIW
- Where
- 41 sites in United States
- Volunteers
- 175 people
- Sponsor
- Akebia Therapeutics
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
A phase 3, multicenter, randomized, double-blind, parallel group study. Anemic subjects with chronic kidney disease (CKD) and not on dialysis will be randomized 1:1 to 1 of 2 dosing strategies to evaluate the proportion of…
- Trial name
- START-CKD (NCT01652872)
- Testing
- Darbepoetin alfa
- Where
- 249 sites in United States, Puerto Rico
- Volunteers
- 756 people
- Sponsor
- Amgen